Press Release

Pleno Inc. Announces First Commercial Agreement with Slopes Bio, Inc.

Immunitas Therapeutics Presents Preclinical Data on IMT-380, a First-in-Class Anti-CD161 Antibody, at FASEB Science Research Conference on Autoimmunity

GC Therapeutics Advances Cell Programming with Systematic Discovery of Transcription Factor Combinations

PRO-101: study design and interim results from a Phase 1 study to evaluate the safety, tolerability, PK, and PD of prosetin in ALS

Aspen Neuroscience Announces 6-Month ASPIRO Phase 1/2a Clinical Trial Results of Personalized Cell Therapy for Parkinson’s Disease

Aspen Neuroscience to Present at the International Society for Gene & Cell Therapy (ISCT) Annual Meeting

GC Therapeutics Expands Leadership Team with Industry Veterans Kai-Hsin Chang and Azadeh Golipour

SonoThera Presents New Data at the 2025 MDA Conference Demonstrating the Potential of Genetic Medicine Using Targeted, Ultrasound-Mediated Delivery (UMD) in Treating Duchenne Muscular Dystrophy

David P. King joins Truvian’s Advisory Board

Aspen Neuroscience Announces Completion of First and Second Cohorts in ASPIRO Phase 1/2a Trial for Parkinson’s Disease